目的 探討固本益腸片聯(lián)合柳氮磺吡啶腸溶片治療輕中度潰瘍性結(jié)腸炎的臨床療效。方法 選取2016年1月—2017年6月黃河三門峽醫(yī)院收治的輕中度潰瘍性結(jié)腸炎患者194例為研究對(duì)象，所有患者隨機(jī)分為對(duì)照組和治療組，每組各97例。對(duì)照組患者口服柳氮磺吡啶腸溶片，1.0 g/次，3次/d。治療組在對(duì)照組的基礎(chǔ)上口服固本益腸片，1.28 g/次，3次/d。兩組均以10 d為1個(gè)療程，療程間隔5 d，連續(xù)治療8個(gè)療程。觀察兩組的臨床療效，比較兩組的臨床癥狀積分、Baron內(nèi)鏡評(píng)分、病變活動(dòng)指數(shù)。結(jié)果 治療后，對(duì)照組和治療組的綜合療效總有效率分別為74.23%、92.78%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，對(duì)照組和治療組的腸鏡療效總有效率分別為80.41%、94.85%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，兩組腹瀉積分、膿血便積分、腹痛積分、里急后重積分、Baron內(nèi)鏡評(píng)分、病變活動(dòng)指數(shù)均明顯下降，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）；且治療組這些觀察指標(biāo)明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。結(jié)論 固本益腸片聯(lián)合柳氮磺吡啶腸溶片治療輕中度潰瘍性結(jié)腸炎具有較好的臨床療效，能改善臨床癥狀，降低病變活動(dòng)指數(shù)，安全性較好，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of Guben Yichang Tablets combined with Sulfasalazine Enteric-coated Tablets in treatment of mild and moderate ulcerative colitis. Methods Patients (194 cases) with mild and moderate ulcerative colitis in Yellow River Sanmenxia Hospital from January 2016 to June 2017 were randomly divided into control and treatment groups, and each group had 97 cases. Patients in the control group were po administered with Sulfasalazine Enteric-coated Tablets, 1.0 g/time, three times daily. Patients in the treatment group were po administered with Guben Yichang Tablets on the basis of the control group, 1.28 g/time, three times daily. With 10 d as 1 course, the course interval was 5 d, and patients in two groups were treated for 8 courses. After treatment, the clinical efficacies were evaluated, and clinical symptom scores, Baron endoscopy scores and lesion activity indexes in two groups were compared. Results After treatment, the comprehensive clinical efficacies in the control and treatment groups were 74.23% and 92.78%, respectively, and there was difference between two groups (P < 0.05). After treatment, the colonoscopy evaluation clinical efficacies in the control and treatment groups were 80.41% and 94.85%, respectively, and there was difference between two groups (P < 0.05). After treatment, diarrhea scores, pus and blood stool scores, abdominal pain scores, tenesmus scores, Baron endoscopy scores, and lesion activity indexes in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Guben Yichang Tablets combined with Sulfasalazine Enteric-coated Tablets has clinical curative effect in treatment of mild and moderate ulcerative colitis, can improve clinical symptoms, decrease lesion activity index, with good safety, which has a certain clinical application value.